Clinical Utility of Micro RNA-148a in Egyptian Patients with Hepatocellular Carcinoma

Bibliographic Information
Authors: Shaaban M.A.A.; Elgohary E.A.; El Assaly N.M.; Hassan M.M.; Amin H.S.; Mohamed K.M.; Ibrahim I.M.; IMostafa M.; Elsawy H.W.; Kabiel W.A.
Journal: Egyptian Journal of Chemistry
Publisher: National Information and Documentation Centre
Publication Date: 19 May 2025
Volume / Issue: Volume 68 / Issue 13
Pages: 461–472
ISSN: 4492285
DOI: 10.21608/ejchem.2025.370092.11493
Scopus: View on Scopus
Document Type: Article
Authors and Affiliations
Shaaban M.A.A., Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Egypt; Elgohary E.A., Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Egypt; El Assaly N.M., Department of Clinical Pathology, Theodor Bilharz Research Institute, Egypt; Hassan M.M., Department of Clinical Pathology, Theodor Bilharz Research Institute, Egypt; Amin H.S., Department of Clinical Pathology, Theodor Bilharz Research Institute, Egypt; Mohamed K.M., Department of Clinical Pathology, Theodor Bilharz Research Institute, Egypt; Ibrahim I.M., Department of Tropical Medicine, Theodor Bilharz Research Institute, Egypt; IMostafa M., Department of Tropical Medicine, Theodor Bilharz Research Institute, Egypt; Elsawy H.W., Department of Clinical Pathology, Theodor Bilharz Research Institute, Egypt; Kabiel W.A., Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Egypt
Abstract
Hepatocellular carcinoma (HCC) is the one of the most commonly diagnosed cancersworldwide and represents one of the leading causes of cancer-related death. HCC is associated with bad prognosis, as most patients present with advanced stages at the time of detection. Aberrant expression of miRNA-148a is found in HCC.This motivatesresearchersto evaluate miR-148a in HCC.The aim of our study was to assess the clinical utility of miR-148a as a non-invasive marker for early detection of HCC in addition to its prognostic value. This study was conducted on 64 subjects, undertitled into three groups: HCC, hepatitis C virus (HCV) and control groups. miR-148a was analyzed in serum by quantitative real time polymerase chain reaction (qRT-PCR). Results showed that miR-148a expression revealed a significant difference between groups with the HCC group revealing the lowest values. The HCC group revealed a negative correlation between miR-148a and primary tumor, tumor size, TNM staging andalpha-fetoprotein(AFP). Receiver operator characteristics (ROC) curve was constructed to estimate discrimination of HCC group versus the other groups through serum biomarker miR-148a and AFP. The best cut-off for miR-148a was ≤ 7.331 (2–ΔΔCT), with sensitivity 82.4 % and specificity 80 %. As for AFP, the best cut-off level was 25 ng/mL with sensitivity 70.6% and specificity 63.3%.As a conclusion, miR-148a was found to be downregulated in Egyptian patients with HCC. Our findings thus propose that miRNA-148a can be beneficial for early diagnosis of HCC, as well as having a prognostic value. © 2025 National Information and Documentation Center (NIDOC)
Keywords
hepatocellular carcinoma; microRNA; microRNA-148a
Citation Information
Scopus Citations: 1
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
